Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products
The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.
You may also be interested in...
Boston Scientific will pay $269m for the 84% of Devoro that it does not already own and up to $67m upon achievement of certain clinical and regulatory milestones.
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.
Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.